Intercept Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
Nov 01, 2017 11:05 am UTC| Business
Worldwide net Ocaliva® (obeticholic acid or OCA) 3Q 2017 sales of $40.9 million (including one-time increase of $4.1M in deferred net revenue)Continuing to advance NASH Phase 3 program: REGENERATE trial in NASH fibrosis on...
Nov 01, 2017 11:05 am UTC| Business
SPOKANE, Wash., Nov. 01, 2017 -- Avista Corp. (NYSE:AVA) today reported net income attributable to Avista Corp. shareholders of $4.5 million, or $0.07 per diluted share for the third quarter of 2017, compared to $12.2...
CDW Declares Cash Dividend of $0.21 Per Share
Nov 01, 2017 11:05 am UTC| Business
LINCOLNSHIRE, Ill., Nov. 01, 2017 -- CDW Corporation (NASDAQ:CDW), today announced that its Board of Directors has declared a quarterly cash dividend of $0.21 per common share to be paid on December 11, 2017 to all...
Bearing Announces the Appointment of Dr. Lee Sungwon of POSCO to the Board of Directors
Nov 01, 2017 11:02 am UTC| Business
VANCOUVER, British Columbia, Nov. 01, 2017 -- Bearing Lithium Corp. ("Bearing" or the "Company") (TSX Venture:BRZ) (OTCQB:BRGRF) (FRANKFURT:B6K1) is pleased to announce the appointment of Dr. Lee Sungwon, a nominee of...
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
Nov 01, 2017 11:01 am UTC| Business
CAMBRIDGE, Mass., Nov. 01, 2017 -- Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today...
Trevena to Report Third Quarter 2017 Financial Results on November 7, 2017
Nov 01, 2017 11:01 am UTC| Business
CHESTERBROOK, Pa., Nov. 01, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call and webcast on Tuesday, November 7, 2017 at 8:00 am EST to review financial results for the quarter...
RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT® for Migraines
Nov 01, 2017 11:01 am UTC| Business
RIZAPORT® is a proprietary oral thin-film formulation of rizatriptan for the treatment of acute migrainesA Prescription Drug User Fee Act (PDUFA) date is expected to be set by the FDA for the first half of 2018, if the...
The “Takaichi Trade”: How Japan’s First Female PM Is Shaping the Yen
How the US–India tariff truce boosts major Indian industries, Surat to Pharma